A universal drug delivery catheter for the treatment of infrapopliteal arterial disease: Results from the multi-center first-in-human study

2017 ◽  
Vol 91 (2) ◽  
pp. 296-301 ◽  
Author(s):  
Frank Bunch ◽  
Craig Walker ◽  
Elias Kassab ◽  
Jeffrey Carr
Keyword(s):  
Drug Delivery ◽  
Human Study ◽  
Arterial Disease ◽  
Delivery Catheter

scholarly journals A universal drug delivery catheter for the treatment of infrapopliteal arterial disease using liquid therapy

2020 ◽  
Vol 96 (2) ◽  
pp. 393-401 ◽  
Author(s):  
Frank Bunch ◽  
Pradeep Nair ◽  
Gaurav Aggarwala ◽  
Eric Dippel ◽  
Elias Kassab ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Arterial Disease ◽  
Delivery Catheter

Atherosclerosis and Nanomedicine Potential: Current Advances and Future Opportunities

2020 ◽  
Vol 27 (21) ◽  
pp. 3534-3554 ◽  
Author(s):  
Fan Jiang ◽  
Yunqi Zhu ◽  
Changyang Gong ◽  
Xin Wei
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Controlled Drug Delivery ◽  
Vascular Wall ◽  
Arterial Disease ◽  
Diagnosis And Treatment ◽  
Antiinflammatory Therapy ◽  
Limited Efficacy ◽  
Conventional Drug ◽  
Diagnostic Modalities

Atherosclerosis is the leading inducement of cardiovascular diseases, which ranks the first cause of global deaths. It is an arterial disease associated with dyslipidemia and changes in the composition of the vascular wall. Besides invasive surgical strategy, the current conservative clinical treatment for atherosclerosis falls into two categories, lipid regulating-based therapy and antiinflammatory therapy. However, the existing strategies based on conventional drug delivery systems have shown limited efficacy against disease development and plenty of side effects. Nanomedicine has great potential in the development of targeted therapy, controlled drug delivery and release, the design of novel specific drugs and diagnostic modalities, and biocompatible scaffolds with multifunctional characteristics, which has led to an evolution in the diagnosis and treatment of atherosclerosis. This paper will focus on the latest nanomedicine strategies for atherosclerosis diagnosis and treatment as well as discussing the potential therapeutic targets during atherosclerosis progress, which could form the basis of development of novel nanoplatform against atherosclerosis.

First in Human Study With a Novel Ingestible Electronic Drug Delivery and Monitoring Device: The Intellicap

2011 ◽  
Vol 140 (5) ◽  
pp. S-766 ◽  
Author(s):  
Peter J. van der Schaar ◽  
Frits Dijksman ◽  
Jeff Shimizu ◽  
Christoph Wanke ◽  
Peter D. Siersema
Keyword(s):  
Drug Delivery ◽  
Human Study ◽  
Monitoring Device

Pharmacokinetics of Paclitaxel Delivery for the Airway by a New Endobronchial Drug Delivery Catheter: Experimental Study

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 85A
Author(s):  
Hisashi Tsukada ◽  
Plamena Entcheva-Dimitrov ◽  
Kirk Seward ◽  
Samaan Rafeq ◽  
Armin Ernst
Keyword(s):  
Drug Delivery ◽  
Experimental Study ◽  
Delivery Catheter

A Surgical Technique for Safely Placing a Drug Delivery Catheter into the Pons of Primates: Preliminary Results of Carboplatin Infusion

Neurosurgery ◽  
2003 ◽  
Vol 52 (5) ◽  
pp. 1169-1177 ◽  
Author(s):  
Phillip B. Storm ◽  
Richard E. Clatterbuck ◽  
Ya J. Liu ◽  
Randolph M. Johnson ◽  
Edward M. Gillis ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Surgical Technique ◽  
Preliminary Results ◽  
Delivery Catheter

scholarly journals Experimental Pilot Study of a Novel Endobronchial Drug Delivery Catheter

2015 ◽  
Vol 22 (4) ◽  
pp. 312-318 ◽  
Author(s):  
Hisashi Tsukada ◽  
Kirk P. Seward ◽  
Samaan Rafeq ◽  
Olivier Kocher ◽  
Armin Ernst
Keyword(s):  
Drug Delivery ◽  
Pilot Study ◽  
Delivery Catheter

A first-in-human study of neural stem cells (NSCs) expressing cytosine deaminase (CD) in combination with 5-fluorocytosine (5-FC) in patients with recurrent high-grade glioma.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 2018-2018 ◽  
Author(s):  
Jana Portnow ◽  
Behnam Badie ◽  
Timothy W. Synold ◽  
Alexander Annala ◽  
Bihong Chen ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Human Study ◽  
Tumor Resection ◽  
Cytosine Deaminase ◽  
High Grade Glioma ◽  
Intracerebral Microdialysis ◽  
High Grade ◽  
Drug Concentrations ◽  
Average Maximum ◽  
The Brain

2018 Background: Human NSCs are inherently tumor-tropic, making them attractive drug delivery vehicles. This pilot-feasibility study assessed the safety of using genetically-modified NSCs for tumor selective enzyme/prodrug therapy. An immortalized, clonal NSC line was retrovirally-transduced to stably express CD, which converts the prodrug 5-FC to 5-fluorouracil (5-FU), producing chemotherapy locally at sites of tumor in the brain. Methods: Patients 18 years or older with recurrent high-grade glioma underwent intracranial administration of NSCs during tumor resection or biopsy. Four days later, 5-FC was administered orally every 6 hours for 7 days. Study treatment was given only once. A standard 3+3 dose escalation schema was used to increase doses of NSCs from 1 x 107 to 5 x 107 and 5-FC from 75 to 150 mg/kg/day. Intracerebral microdialysis was performed to measure brain levels of 5-FC and 5-FU; serial blood samples were obtained to assess systemic drug concentrations. Three patients received iron-labeled NSCs for MRI tracking. Brain autopsies were done on 2 patients. Results: Fifteen patients received study treatment. Three were inevaluable for toxicity and replaced. All patients tolerated the NSCs well. There was 1 dose-limiting toxicity (grade 3 transaminitis) possibly related to 5-FC. At the highest dose level of NSCs, the average steady-state concentration of 5-FU in the brain was 63.9±7.9 nM. The average maximum 5-FU level in brain was 104±88 nM compared to 24±36 nM in plasma, indicating local production of 5-FU in the brain by the NSCs. MR imaging of iron-labeled NSCs showed preliminary evidence of NSC migration. Autopsy data documented (by IHC, FISH, and PCR) NSCs at distant sites of tumor in the brain and no development of secondary tumors. Conclusions: This first-in-human study has demonstrated safety and proof-of-concept regarding NSC-mediated conversion of 5-FC to 5-FU and NSC tumor-tropism. NSCs have the potential to overcome obstacles of drug delivery that limit current gene therapy strategies. Results of this pilot study will serve as the foundation for future NSC studies. (Supported by NCI 1R21 CA137639-01A1, CIRM DR-01421). Clinical trial information: NCT01172964.

scholarly journals Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis

2018 ◽  
Author(s):  
Sunandita Sarker ◽  
Yiannis S. Chatzizisis ◽  
Srivatsan Kidambi ◽  
Benjamin S. Terry
Keyword(s):  
Drug Delivery ◽  
High Risk ◽  
Arterial Wall ◽  
Local Treatment ◽  
Specific Treatment ◽  
Modern World ◽  
Design And Development ◽  
Anti Inflammatory ◽  
Delivery Catheter

Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations have confirmed that atherosclerosis is an inflammatory disease [3] [4] [5]. This confirmation has opened the treatment of this disease to many novel anti-inflammatory therapeutics. The use of nanoparticle-nanomedicines has gained popularity over recent years. Initially approved as anticancer treatment therapeutics [6], nanomedicine also holds promise for anti-inflammatory treatment, personalized medicine, target-specific treatment, and imaging of atherosclerotic disease [7]. The primary aim of this collaborative work is to develop and validate a novel strategy for catheter-directed local treatment of high-risk plaque using anti-inflammatory nanoparticles. Preselected drugs with the highest anti-inflammatory efficacy will be incorporated into a novel liposome nanocarrier, and delivered in-vivo through a specially designed catheter to high-risk atherosclerotic plaques. The catheter has specially designed perfusion pores that inject drug into the blood stream in such a controlled manner that the streamlines carry the nanoparticles to the stenotic arterial wall. Once the particles make it to the arterial wall, they can be absorbed into the inflamed tissue. In this paper, we discuss the design and development of an atraumatic drug delivery catheter for the administration of lipid nanoparticles.

Sign in / Sign up

Export Citation Format

Share Document